Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2018
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 05 Jul 2018 Planned End Date changed from 1 Jun 2020 to 1 Jun 2022.
- 05 Jul 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2019.
- 14 Aug 2017 New trial record